Tirzepatide lowered HbA1c by 2.01%, 2.24%, and 2.30% at doses of 5, 10, and 15 mg, respectively
doi:10.1093/ajcn/76.4.897
The compounds described herein can be used for both human clinical medicine and veterinary applications
Many clinics and providers are hesitant to start anti-obesity medications due to provider inexperience and less depth of understanding about the safety and efficacy of available treatments
Int J Pharm 588:119798
Ultimately, oral Wegovy offers a new, effective option for weight management in individuals who cannot tolerate using the injectable format, thus helping a wider cohort of patients to reduce excess body weight, improve weight-related medical problems, and lower their risk of major cardiovascular events, all under the guidance of their healthcare providers